Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ASCO Annual Meeting 2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

2024 ASCO Annual Meeting

Keep up to date with all the top stories and latest evidence with our hub page, including official congress videos and expert takeaways.
ADVANCED SEARCH
Log in
Top
Investigational New Drugs
Published in: Investigational New Drugs 4/2005

01-08-2005

Second-line treatment with oxaliplatin, leucovorin and 5-fluorouracil in gemcitabine-pretreated advanced pancreatic cancer: A phase II study

Authors: Nicolas Tsavaris, Christos Kosmas, Helias Skopelitis, Panagiotis Gouveris, Petros Kopteridis, Dioynissis Loukeris, Frantzeska Sigala, Alexandra Zorbala-Sypsa, Evangelos Felekouras, Efstathios Papalambros

Published in: Investigational New Drugs | Issue 4/2005

Login to get access
Metadata
Title
Second-line treatment with oxaliplatin, leucovorin and 5-fluorouracil in gemcitabine-pretreated advanced pancreatic cancer: A phase II study
Authors
Nicolas Tsavaris
Christos Kosmas
Helias Skopelitis
Panagiotis Gouveris
Petros Kopteridis
Dioynissis Loukeris
Frantzeska Sigala
Alexandra Zorbala-Sypsa
Evangelos Felekouras
Efstathios Papalambros
Publication date
01-08-2005
Publisher
Kluwer Academic Publishers
Published in
Investigational New Drugs / Issue 4/2005
Print ISSN: 0167-6997
Electronic ISSN: 1573-0646
DOI
https://doi.org/10.1007/s10637-005-1446-y

Other articles of this Issue 4/2005

Investigational New Drugs 4/2005 Go to the issue

Erratum

Phase I Study of Tomudex and Doxorubicin in Patients with Locally Advanced, Inoperable or Metastatic Cancer (IND.98)

OriginalPaper

Enhanced P53 and BAX gene expression and apoptosis in A549 cells by cis-Pt(II) complex of 3-aminoflavone in comparison with cis-DDP

OriginalPaper

BBR 3438, a novel 9-aza-anthrapyrazole, in patients with advanced gastric cancer: A phase II study group trial of the central European Society of Anticancer-Drug Research (CESAR)

OriginalPaper

A phase I pharmacokinetic study of the P-glycoprotein inhibitor, ONT-093, in combination with paclitaxel in patients with advanced cancer

OriginalPaper

Phase II study of CCI-779 in patients with recurrent glioblastoma multiforme

Erratum

Pomegranate (Punica granatum) Pure Chemicals Show Possible Synergistic Inhibition of Human PC-3 Prostate Cancer Cell Invasion Across Matrigeltm

2024 ASCO Annual Meeting Coverage

Highlights of the Day: Breast cancer – metastatic

Breast Cancer Video

In this session, Dr. Wolff provides his key takeaways from the data presented in the metastatic breast cancer oral abstract session at ASCO 2024.

Watch now

Highlights of the Day: Gynecologic cancer

Gynecologic Cancer Video

Highlights of the Day: Breast Cancer – local/regional/adjuvant

Breast Cancer Video

Neoadjuvant dual immunotherapy improves melanoma outcomes

04-06-2024 Melanoma News

» View more highlights on the ASCO 2024 congress hub page

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits